remedium bio

Remedium Bio is a Boston based gene therapy company focused on the development of highly innovative treatments for a broad range of diseases. The Remedium approach utilizes proven scientific fundamentals, in a novel way, to treat the most debilitating conditions. Starting with well-characterized pathophysiological principles, our scientists modularly apply proven technologies to quickly advance curative treatments through the R&D cycle. Today, our leading candidates include gene therapy treatments in the fields of Endocrinology, Cardiology, Hematology, and Rheumatology.

treatment modalities

  • Cardiology
    Myocardial Infarction

    Cardiovascular disease is the leading cause of death in the world and many developed and developing countries. With over 1.5 M annual cases of myocardial infarction in the US alone, and a nearly 25% - 1 year and over 50% - 2 year mortality rates despite availability of a broad range of efficacious treatment options, the disease remains the most debilitating condition facing mankind in the modern era. Remedium’s unique gene therapy approach utilizes proven therapeutic targets to tilt the landscape toward longer-term survival, in favor of the patient by promoting repopulation of infarcted tissues with functioning cardiomyocytes.

  • Endocrinology
    Diabetes

    Type 1 Diabetes is an autoimmune disease caused by cell-mediated destruction of Beta cells. Type 2 Diabetes is a metabolic disorder caused predominantly by Beta cell insufficiency and insulin resistance. In both cases, the patients typically progress to the current gold-standard therapy, which is limited to managing symptoms via lifelong insulin replacement by subcutaneous injection of recombinant proteins. In parallel, several investigational approaches attempt to replace beta-cells with protective exterior or molecular barriers, however, significant safety hurdles and uncertainty over long-term efficacy remain. The Remedium approach utilizes genetic engineering and clinically-proven delivery systems, to prevent the onset and progression of Type 1 Diabetes – stopping the disease prior to immune-mediated destruction of the insulin producing cells or genetically supplement insulin production for Type 2 Diabetes patients potentiating insulin independence.

  • Hematology
    Circulating Enzyme Deficiency

    A number of genetic and acquired diseases of the blood arise from inactivating mutations or insufficiencies of circulating proteins; most notably globulins and complement system proteins. Several of these proteins have been demonstrated to decline with age, potentially resulting in increased risk of developing opportunistic infections and autoimmune diseases. Remedium’s platform technology is uniquely positioned to augment or replace the function of specific hematological components to prevent overt pathology.

  • Rheumatology
    Diseases of Aging

    Immune-mediated destruction of tissues that results from overt autoimmune pathology or is derived from natural aging processes coupled with normal tissue degradation causes a broad spectrum of rheumatological conditions. At the interface of aging and inflammation is the central dogma of organ failure and aging. These pathologies, coupled with a decline of growth factors tilt the scales in favor of degenerative processes eroding organ and tissue function – essentially resulting in organismal aging. Remedium Bio is developing a safety-switch protected, growth factor supplementation platform to restore functionality of a broad range of organs, cells, and tissues.

REMEDIUM PIPELINE

The Remedium Bio pipeline consists of a broad range of therapies for immune and age related conditions. The treatment modalities are founded in proven scientific fundamentals and focused on therapeutic treatments using a novel approach.

Screenshot
Background

There is so much to life

The only worthy purpose is saving it!

proven fundamentals

Remedium therapies are based on proven fundamental components including clinically validated targets, commercial delivery vectors, and time-tested manufacturing technologies.

novel approach

The technology is then applied to treating disease using a fundamentally novel, patent pending approach. An approach, uniquely matched specifically with the target condition.

Infinite Potential

Each technology serves as a potential platform, from treating conditions resulting from age related decline, to replacing extracellular proteins in a safe and adjustable way.

Get In Touch

We are always interested in starting a new conversation and are looking forward to hearing from you. Thank you in advance for your inquiry and please have a wonderful day!

1116 Great Plain Ave, Suite 203                        
Needham, MA                        
02492

E: info@remedium-bio.com 
P: +1 (978) 467 5217